(Reuters) - Pfizer Inc and Moderna Inc said on Tuesday they will be ready with COVID-19 vaccines designed to combat the BA.1 Omicron variant that was dominant last winter earlier than those designed to target currently dominant versions of Omicron.
Moderna said it would be ready with a "couple of hundred million" bivalent vaccines designed to combat BA.1 by September, but it would be late October or early November if the vaccine maker needed to design a vaccine to combat the currently dominant BA.4 and BA.5 sublineages.
Pfizer said it has a significant amount of BA.1 vaccine produced already and is preparing to produce a large amount of vaccine against BA.4 and BA.5. It said either vaccine could be ready for an early October rollout.
Reuters Health Information © 2022